ArticleBMC urology2026
Bladder-sparing chemoradiotherapy following neoadjuvant chemotherapy for muscle-invasive bladder cancer: a retrospective cohort study.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRadical cystectomy following cisplatin-based neoadjuvant chemotherapy (NAC) is still the standard approach for managing muscle-invasive bladder cancer (MIBC); however, a substantial proportion of patients are not candidates for surgery or cisplatin-based chemotherapy. The role of NAC followed by chemoradiation (CRT) in a bladder-preserving approach is not well established. This study aimed to evaluate the feasibility, survival outcomes, and prognostic factors associated with NAC followed by definitive CRT. MATERIALS AND
methodsWe retrospectively analyzed MIBC patients treated with NAC and subsequent CRT between 2010 and 2023. Overall survival (OS) and event-free survival (EFS) were analyzed using the Kaplan-Meier method and Cox proportional hazards models.
resultsAmong 224 MIBC patients treated with NAC, 132 patients received bladder-preserving CRT after NAC. The median OS for the entire cohort was 58 months (95% CI: 37.63-78.37). Median OS was significantly longer in patients with clinical complete response (cCR) compared with those without (73 vs. 29 months, p = 0.007). Median EFS was also superior in the cCR group (50 vs. 23 months, p = 0.022). In multivariable Cox regression analysis, achievement of cCR was independently associated with superior OS (HR 0.52, 95% CI 0.30-0.92, p = 0.028) and EFS (HR 0.54, 95% CI 0.32-0.93, p = 0.036). Moreover, the presence of baseline hydronephrosis predicted significantly worse OS (HR 2.37, 95% CI 1.32-4.25, p = 0.006) but showed no association with EFS. The type of NAC regimen (cisplatin vs. carboplatin) had no independent effect on survival.
conclusionNAC followed by CRT is a feasible bladder-preserving approach for selected patients with MIBC, including those ineligible for cystectomy or cisplatin. Achievement of cCR is the most robust prognostic factor for both OS and EFS, supporting its role as a surrogate endpoint in this setting. These findings provide novel evidence for integrating NAC into bladder-preserving strategies and highlight clinical factors that may guide individualized treatment selection. A prospective randomized trial is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.